Results 161 to 170 of about 63,050 (312)

Plasma and urinary exposure of cannabidiol and cannabidiolic acid in horses following consumption of contaminated feed. [PDF]

Ir Vet J
Ekstrand C, Michanek P, Hernlund E, Gehring R, Salomonsson M.   +4 more
europepmc   +1 more source

Exploring the safety of cannabidiol (CBD)

Cannabidiol (CBD), a naturally occurring cyclic terpenoid found in Cannabis sativa L., is renowned for its diverse pharmacological benefits. Marketed as a remedy for various health issues, CBD products are utilized by patients as a supplementary therapy ...
Žabkar, Sonja, Filipič, Metka, Žegura, Bojana, Novak, Matjaž, Kološa, Katja, Štern, Alja, Trontelj, Jurij, Šentjurc, Tjaša   +7 more
core   +1 more source

Enteral Nutrition in Idiopathic Parkinson's Disease and Atypical Parkinsonism: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dysphagia and malnutrition are common in advanced Parkinson's disease and atypical parkinsonism. There is a lack of evidence to guide the use of enteral nutrition in these situations, including whether it improves survival or reduces aspiration pneumonia.
Bradley Lonergan, Matteo Ciocca, Anette Schrag, Yen Tai   +3 more
wiley   +1 more source

Cannabidiol Protects Against 1-Methyl-4-Phenylpyridinium and Manganese-Induced Neurotoxicity via Nod-Like Receptor Protein 3 Inflammasome Suppression. [PDF]

J Biochem Mol Toxicol
Demirel G, Yirün A, Çakir DA, Özkan H, Güneş BŞ, Selvi S, Öztürk YE, Erkekoğlu P.   +7 more
europepmc   +1 more source

Biomarkers of Leucine‐Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Movement Disorders, EarlyView.
Abstract Background Common and rare genetic variants in leucine‐rich repeat kinase 2 (LRRK2) have been linked with sporadic and familial Parkinson's disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP).
Louise‐Kristine Nielsen, Joshua L.I. Frost, David P. Vaughan, Raquel Real, Riona Fumi, Marte Theilmann Jensen, Megan Hodgson, Eleanor J. Stafford, Lesley Wu, Olaf Ansorge, Annelies Quaegebeur, Kieren S.J. Allinson, Thomas T. Warner, Zane Jaunmuktane, Anjum Misbahuddin, P. Nigel Leigh, Boyd C.P. Ghosh, Kailash P. Bhatia, Alistair Church, Christopher Kobylecki, Michele T.M. Hu, James B. Rowe, Alan A. Shomo, Danielle L. Graham, Omar S. Mabrouk, Huw R. Morris, Esther M. Sammler, Edwin Jabbari   +27 more
wiley   +1 more source

Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review. [PDF]

Front Vet Sci
Medina FJ, Torres CG.
europepmc   +1 more source

Co‐ and Multi‐Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review

Movement Disorders, EarlyView.
Abstract Parkinson's disease (PD) has been historically defined as a disease of striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the substantia nigra pars compacta, related to the presence of Lewy bodies and Lewy neurites.
Michele Matarazzo, Per Borghammer, Inas Elsayed, Jennifer G. Goldman, Yue Huang, Katja Lohmann, Per Svenningsson, Lorraine V. Kalia, Daniela Berg, Jeffrey H. Kordower, the MDS Scientific Issues Committee   +10 more
wiley   +1 more source

High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. [PDF]

EClinicalMedicine
Robertson RV, Suraev A, McCartney D, Peng A, Meylakh N, Gordon R, Tinoco-Mendoza FA, Morse C, Sattarov L, Boswell-Ruys CL, Keay KA, Cairns EA, Shetty S, McGregor IS, Henderson LA.   +14 more
europepmc   +1 more source

Quantitation of Cannabidiol (CBD) in brain regions and plasma following intranasal administration of a CBD nanoformulation

Background and objective Delivering therapeutic drugs to the brain for neurological disorders remains challenging due to the restrictive nature of the blood–brain barrier (BBB).
Pranav Patel, Juan Sanchez-Ramos, Oksana Fihurka, Gunjan Upadhyay   +3 more
core   +1 more source

A Brainstem Radiomics Framework to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Differentiating progressive supranuclear palsy (PSP) from Parkinson's disease (PD) can be clinically challenging. In the neuroimaging field, radiomics has emerged as a promising approach to capture subtle microstructural and textural image alterations, improving differential diagnoses.
Chiara Camastra, Jolanda Buonocore, Antonio Augimeri, Camilla Calomino, Maria Giovanna Bianco, Alessia Sarica, Pier Paolo Arcuri, Aldo Quattrone, Andrea Quattrone   +8 more
wiley   +1 more source